



(12) **United States Patent**
Hayer et al.

(10) **Patent No.:** **US 9,623,066 B2**
(45) **Date of Patent:** ***Apr. 18, 2017**

(54) **COMPOSITIONS AND METHODS TO INHIBIT KIDNEY STONE GROWTH**

FOREIGN PATENT DOCUMENTS

(71) Applicant: **KIDNEY STONE LABORATORIES, INC.**, Fort Lauderdale, FL (US)

RO 80051 A2 * 10/1982

(72) Inventors: **Gregory K. Hayer**, Fort Lauderdale, FL (US); **Brendan Magrab**, Westfield, NJ (US); **Henry R. Wolfe, Jr.**, Glenmoore, PA (US)

OTHER PUBLICATIONS

(73) Assignee: **KIDNEY STONE LABORATORIES, INC.**, Fort Lauderdale, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

“Complications from kidney stone treatments are common, costly”; Science Daily;Duke University Medical Center;Apr. 2014; <http://www.sciencedaily.com/releases/2014/04/140428094257.htm> [retrieved on Aug. 19, 2015]; 2 pages.

This patent is subject to a terminal disclaimer.

“6 Easy Ways to Prevent Kidney Stones”; National Kidney Foundation; 2015; https://www.kidney.org/atoz/content/kidneystones_prevent [retrieved on Aug. 19, 2015]; 2 pages.

(21) Appl. No.: **15/266,464**

“Diet for Kidney Stone Prevention”; NIH; Feb. 2013;The National Institute of Diabetes and Digestive and Kidney Diseases, NIH Publication No. 13-6425, 8 pages.

(22) Filed: **Sep. 15, 2016**

“How Can Kidney Stones Be Prevented?”; The Johns Hopkins School of Medicine; The James Buchanan Brady Urological Institute;Accessed Aug. 31, 2015; <http://urology.jhu.edu/kidney/STONESprevention.php>; 3 pages.

(65) **Prior Publication Data**

US 2017/0065658 A1 Mar. 9, 2017

Allie-Hamdulay; Prophylactic and therapeutic properties of a sodium citrate preparation in the management of calcium oxalate urolithiasis: randomized, placebo-controlled trial; Urol Res;vol. 33; 2005; pp. 116-124.

Related U.S. Application Data

(60) Division of application No. 15/059,644, filed on Mar. 3, 2016, now Pat. No. 9,492,491, which is a continuation-in-part of application No. 14/960,692, filed on Dec. 7, 2015, which is a continuation of application No. 14/845,612, filed on Sep. 4, 2015, now Pat. No. 9,233,135.

Barcelo et al.; “Randomized Double-Blind Study of Potassium Citrate in Idiopathic Hypocitraturic Calcium Nephrolithiasis”; The Journal of Urology, vol. 150; 1993; pp. 1761-1764.

(51) **Int. Cl.**

- A61K 36/00** (2006.01)
- A61K 36/88** (2006.01)
- A61K 31/194** (2006.01)
- A61K 33/06** (2006.01)
- A61K 31/6615** (2006.01)
- A61K 31/4415** (2006.01)
- A61K 9/00** (2006.01)
- A61K 9/48** (2006.01)

Chow et al.; “Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones”; Kidney International, vol. 65; 2004; pp. 1724-1730.

(52) **U.S. Cl.**

CPC **A61K 36/88** (2013.01); **A61K 9/0053** (2013.01); **A61K 9/48** (2013.01); **A61K 31/194** (2013.01); **A61K 31/4415** (2013.01); **A61K 31/6615** (2013.01); **A61K 33/06** (2013.01)

Chow et al.;“A stone farm: development of a method for simultaneous production of multiple calcium oxalate stones in vitro”; Urol Res, vol. 32; 2004; pp. 55-60.

(58) **Field of Classification Search**

None
See application file for complete search history.

Coe (2015); “Citrate to Prevent Calcium and Uric Acid Stones”; University of Chicago Kidney Stone Evaluation and Treatment Program; <http://kidneystones.uchicago.edu/citrate-to-prevent-stones/> [retrieved on Aug. 19, 2015];8 pages.

(56) **References Cited**

U.S. PATENT DOCUMENTS

- 2013/0302448 A1* 11/2013 Parc A61K 8/55 424/725
- 2013/0337057 A1* 12/2013 Patankar A61K 36/185 424/451

Coe et al.; “The Pathogenesis and Treatment of Kidney Stones”; N Engl J Med, vol. 327; 1992; pp. 1141-1152 (abstract only).

Costa-Bauza et al.; “Factors affecting calcium oxalate dihydrate fragmented calculi regrowth” BMC Urology, vol. 6, No. 16, 2006; 7 pages.

Ettlinger et al.; “Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis”; J Urol., vol. 158; 1997; pp. 2069-2073.

Fabris et al.; “Long-Term Treatment with Potassium Citrate and Renal Stones in Medullary Sponge Kidney”; Clin J Am Soc Nephrol., vol. 5, No. 9; 2010; pp. 1663-1668.

Forbes et al.; “Effects of Dietary Phytate, Calcium and Magnesium Levels on Zinc Bioavailability to Rats”; J. Nutr., vol. 114; 1984; pp. 1421-1425.

Foster et al.; “Emergency Department Visits and Hospital Admissions for Kidney Stone Disease,2009”;Healthcare Cost and Utilization Project; Statistical Brief # 139, Jul. 2012, Agency for Healthcare Research and Quality, Rockville, MD. Available at <http://www.hcup-us.ahrq.gov/reports/statbriefs/sb139.pdf> [retrieved on Aug. 19, 2015];10 pages.

(Continued)

Primary Examiner — Qiuwen Mi
(74) Attorney, Agent, or Firm — Cantor Colburn LLP

(57) **ABSTRACT**

An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.